Inhibition of Prolyl Hydroxylase Domain-Containing Protein Downregulates Vascular Angiotensin II Type 1 Receptor

被引:23
|
作者
Matsuura, Hirohide [1 ]
Ichiki, Toshihiro [2 ]
Ikeda, Jiro
Takeda, Kotaro [2 ]
Miyazaki, Ryohei
Hashimoto, Toru
Narabayashi, Eriko
Kitamoto, Shiro [2 ]
Tokunou, Tomotake
Sunagawa, Kenji
机构
[1] Kyushu Univ, Grad Sch Med Sci, Dept Cardiovasc Med, Higashi Ku, Fukuoka 8128582, Japan
[2] Kyushu Univ, Grad Sch Med Sci, Dept Adv Therapeut Cardiovasc Dis, Fukuoka 8128582, Japan
关键词
angiotensin II type 1 receptor; renin angiotensin system; prolyl hydroxylase domain-containing protein; vascular remodeling; HYPOXIA-INDUCIBLE-FACTOR; IMPROVED PATIENT OUTCOMES; RAT CARDIAC FIBROBLASTS; NECROSIS-FACTOR-ALPHA; GENE-EXPRESSION; TRANSCRIPTION FACTOR; CLINICAL-EVIDENCE; AT(1) RECEPTOR; MESSENGER-RNA; RENAL-DISEASE;
D O I
10.1161/HYPERTENSIONAHA.110.167106
中图分类号
R6 [外科学];
学科分类号
1002 ; 100210 ;
摘要
Inhibition of prolyl hydroxylase domain-containing protein (PHD) by hypoxia stabilizes hypoxia-inducible factor 1 and increases the expression of target genes, such as vascular endothelial growth factor. Although the systemic renin-angiotensin system is activated by hypoxia, the role of PHD in the regulation of the renin-angiotensin system remains unknown. We examined the effect of PHD inhibition on the expression of angiotensin II type 1 receptor (AT(1)R). Hypoxia, cobalt chloride, and dimethyloxalylglycine, all known to inhibit PHD, reduced AT(1)R expression in vascular smooth muscle cells. Knockdown of PHD2, a major isoform of PHDs, by RNA interference also reduced AT(1)R expression. Cobalt chloride diminished angiotensin II-induced extracellular signal-regulated kinase phosphorylation. Cobalt chloride decreased AT(1)R mRNA through transcriptional and posttranscriptional mechanisms. Oral administration of cobalt chloride (14 mg/kg per day) to C57BL/6J mice receiving angiotensin II infusion (490 ng/kg per minute) for 4 weeks significantly attenuated perivascular fibrosis of the coronary arteries without affecting blood pressure level. These data suggest that PHD inhibition may be beneficial for the treatment of cardiovascular diseases by inhibiting renin-angiotensin system via AT(1)R downregulation. (Hypertension. 2011;58:386-393.)
引用
收藏
页码:386 / U119
页数:25
相关论文
共 50 条
  • [21] SIRT1, a longevity gene, downregulates angiotensin II type 1 receptor expression in vascular smooth muscle cells
    Miyazaki, Ryohei
    Ichiki, Toshihiro
    Hashimoto, Toru
    Inanaga, Keita
    Imayama, Ikuyo
    Sadoshima, Junichi
    Sunagawa, Kenji
    ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY, 2008, 28 (07) : 1263 - 1269
  • [22] Hyperglycemia-Induced Inhibition of the Angiotensin II Type 1 Receptor Pathway in the Vascular Endothelium
    Hoffmann, Brian
    Haspula, Dhanush
    FASEB JOURNAL, 2020, 34
  • [23] Angiotensin II Type 1 Receptor Mediates Angiotensin II Inhibition on BKCa Channels
    Zhang, Zhu
    Lu, Rong
    Stefani, Enrico
    Toro, Ligia
    BIOPHYSICAL JOURNAL, 2012, 102 (03) : 691A - 691A
  • [24] Inhibition of Hypoxia-inducible Factor-targeting Prolyl Hydroxylase Domain-containing Protein 2 (PHD2) Enhances Matrix Synthesis by Human Chondrocytes
    Thoms, Brendan L.
    Murphy, Christopher L.
    JOURNAL OF BIOLOGICAL CHEMISTRY, 2010, 285 (27) : 20472 - 20480
  • [25] SIRT1, a longevity gene, downregulates angiotensin II type 1 receptor expression
    Miyazaki, R.
    Ichiki, T.
    Sunagawa, K.
    JOURNAL OF HYPERTENSION, 2008, 26 : S521 - S522
  • [26] Resveratrol downregulates angiotensin II type 1 receptor through activation of SIRT1
    Miyazaki, Rhouhei
    Ichiki, Toshihiro
    Inanaga, Keita
    Imayama, Ikuyo
    Sunagawa, Kenji
    HYPERTENSION, 2007, 50 (04) : E103 - E103
  • [27] Inhibition of Atherosclerosis by Angiotensin II Type 1 Receptor Antagonists
    Stefan Peters
    American Journal of Cardiovascular Drugs, 2013, 13 : 221 - 224
  • [28] Inhibition of Atherosclerosis by Angiotensin II Type 1 Receptor Antagonists
    Peters, Stefan
    AMERICAN JOURNAL OF CARDIOVASCULAR DRUGS, 2013, 13 (04) : 221 - 224
  • [29] Prolyl hydroxylase domain-containing protein inhibitors as stabilizers of hypoxia-inducible factor: small molecule-based therapeutics for anemia
    Yan, Lin
    Colandrea, Vincent J.
    Hale, Jeffrey J.
    EXPERT OPINION ON THERAPEUTIC PATENTS, 2010, 20 (09) : 1219 - 1245
  • [30] Angiotensin II type 1 receptor expression in human pancreatic cancer and growth inhibition by angiotensin II type 1 receptor antagonist
    Fujimoto, Y
    Sasaki, T
    Tsuchida, A
    Chayama, K
    FEBS LETTERS, 2001, 495 (03) : 197 - 200